<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01504971</url>
  </required_header>
  <id_info>
    <org_study_id>20111013-001</org_study_id>
    <nct_id>NCT01504971</nct_id>
  </id_info>
  <brief_title>Narrow-band Imaging, Autofluorescence Imaging and Gastroesophageal Reflux Disease</brief_title>
  <official_title>Diagnostic Value of Narrow-band Imaging, Autofluorescence Imaging &amp; White-light Imaging on Gastroesophageal Reflux Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of this study is to compare the efficacy of narrow band imaging (NBI) and
      autofluorescence imaging (AFI) to distinguish subtle mucosal change related to acid reflux
      that is not visible in standard white light imaging (WLI) endoscopy, and help indicating the
      diagnosis of gastroesophageal reflux disease (GERD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      GERD is a common condition that develops when the reflux of gastric and/or duodenal contents
      causes troublesome symptoms with or without mucosal damage or complications. Despite the high
      prevalence of GERD in the general population, up to 60% of patients with reflux symptoms is
      insufficiently characterized as having normal endoscopic finding based on standard WLI
      endoscopy: non-erosive reflux diseases (NERD).

      NBI is an optical-digital imaging technology that uses two specific narrow-banded shot
      wavelength lights (400-430 nm and 525-555 nm) instead of broad band white light. The NBI
      contrasts surface structure and vascular architecture of the superficial mucosa and
      facilitates evaluation of indistinct mucosal morphology. AFI produces real-time computed
      images of endoscopically detected autofluorescence emitted from endogenous fluorophores in
      the digestive tract (collagen, nicotinamide, adenine dinucleotide, flavin, and porphyrins)
      caused by light excitation. The AFI can identify lesions due to differences in tissue
      fluorescence properties that are not detectable by standard WLI. Hence, our hypothesis is
      that new endoscopic imaging i.e. NBI and AFI would help to identify subtle mucosal change
      which indicates the diagnosis of GERD
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic Ability of Each Endoscopic Finding for GERD Symptom.</measure>
    <time_frame>1 month</time_frame>
    <description>Patients with GERD symptom receive endoscopic tri-modal imaging within 1 month</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Association of Each Endoscopic Finding With Symptom Score</measure>
    <time_frame>1 month</time_frame>
    <description>Symptom score is assessed by a self-reported questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of Each Endoscopic Finding With pH Monitoring Result</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of Each Endoscopic Finding With Treatment Effect of PPI</measure>
    <time_frame>2 month</time_frame>
    <description>Treatment effect of PPI is assessed by changes of symptom score</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">95</enrollment>
  <condition>Gastroesophageal Reflux Disease</condition>
  <arm_group>
    <arm_group_label>Gastroesophageal reflux disease (GERD)</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>symptom questionaire</intervention_name>
    <description>GerdQ questionaire</description>
    <arm_group_label>Gastroesophageal reflux disease (GERD)</arm_group_label>
    <other_name>GERD symptom questionaire</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>pH monitoring</intervention_name>
    <description>24-hour pH monitoring</description>
    <arm_group_label>Gastroesophageal reflux disease (GERD)</arm_group_label>
    <other_name>Device was from Sierra Company</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Tri-modal imaging endoscopy</intervention_name>
    <description>To investigate WLI,NBI and AFI</description>
    <arm_group_label>Gastroesophageal reflux disease (GERD)</arm_group_label>
    <other_name>Device was from Olympus Company</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rabeprazole</intervention_name>
    <description>10mg, bid, p.o.</description>
    <arm_group_label>Gastroesophageal reflux disease (GERD)</arm_group_label>
    <other_name>PPI therapy</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients presented with reflux symptoms in outpatient clinic of a general hospital.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        1. Inclusion criteria

               -  GERD symptom: heartburn or regurgitation (either one) at least 2 days a week

               -  Presence of symptom for longer than 1 month before screening

               -  Provision of written informed consent

          2. Exclusion criteria:

               -  Any known esophageal disease or disorder, other than reflux esophagitis

               -  Active or healing gastroduodenal ulcer (except scars)

               -  History of esophageal or gastric surgery.

               -  Clinically significant heart, lung, liver or kidney disease

               -  Allergy to proton-pump inhibitor

               -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shuzhang Li, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Chinese PLA General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Outpatient Department Building</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Fock KM, Teo EK, Ang TL, Tan JY, Law NM. The utility of narrow band imaging in improving the endoscopic diagnosis of gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2009 Jan;7(1):54-9. doi: 10.1016/j.cgh.2008.08.030. Epub 2008 Sep 3.</citation>
    <PMID>18852068</PMID>
  </results_reference>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2012</study_first_submitted>
  <study_first_submitted_qc>January 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2012</study_first_posted>
  <results_first_submitted>August 4, 2015</results_first_submitted>
  <results_first_submitted_qc>August 4, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 2, 2015</results_first_posted>
  <last_update_submitted>August 4, 2015</last_update_submitted>
  <last_update_submitted_qc>August 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Yunsheng Yang</investigator_full_name>
    <investigator_title>Professor, Department of Gastroenterology and Hepatology</investigator_title>
  </responsible_party>
  <keyword>Gastroesophageal Reflux;</keyword>
  <keyword>Endoscopy;</keyword>
  <keyword>Esophageal pH monitoring;</keyword>
  <keyword>Narrow band imaging;</keyword>
  <keyword>Autofluorescence imaging;</keyword>
  <keyword>White light imaging;</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rabeprazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Gastroesophageal Reflux Disease (GERD)</title>
          <description>symptom questionaire: GerdQ questionaire
pH monitoring: 24-hour pH monitoring
Tri-modal imaging endoscopy: To investigate WLI,NBI and AFI
rabeprazole: 10mg, bid, p.o.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="95"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Gastroesophageal Reflux Disease (GERD)</title>
          <description>symptom questionaire: GerdQ questionaire
pH monitoring: 24-hour pH monitoring
Tri-modal imaging endoscopy: To investigate WLI,NBI and AFI
rabeprazole: 10mg, bid, p.o.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="95"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Diagnostic Ability of Each Endoscopic Finding for GERD Symptom.</title>
        <description>Patients with GERD symptom receive endoscopic tri-modal imaging within 1 month</description>
        <time_frame>1 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Participants</title>
            <description>Diagnostic capabilities of White-light Imaging on Gastroesophageal Reflux Disease</description>
          </group>
          <group group_id="O2">
            <title>Participants Same to arm1</title>
            <description>Diagnostic capabilities of Autofluorescence Imaging on Gastroesophageal Reflux Disease</description>
          </group>
          <group group_id="O3">
            <title>Participants Same to Previous Arm</title>
            <description>Diagnostic capabilities of GerdQ in the diagnosis of GERD</description>
          </group>
        </group_list>
        <measure>
          <title>Diagnostic Ability of Each Endoscopic Finding for GERD Symptom.</title>
          <description>Patients with GERD symptom receive endoscopic tri-modal imaging within 1 month</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" lower_limit="9" upper_limit="32"/>
                    <measurement group_id="O2" value="77" lower_limit="65" upper_limit="89"/>
                    <measurement group_id="O3" value="60" lower_limit="45" upper_limit="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Association of Each Endoscopic Finding With Symptom Score</title>
        <description>Symptom score is assessed by a self-reported questionnaire</description>
        <time_frame>1 month</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Association of Each Endoscopic Finding With pH Monitoring Result</title>
        <time_frame>1 month</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Association of Each Endoscopic Finding With Treatment Effect of PPI</title>
        <description>Treatment effect of PPI is assessed by changes of symptom score</description>
        <time_frame>2 month</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Participants</title>
          <description>Diagnostic capabilities of WLI in the diagnosis of GERD</description>
        </group>
        <group group_id="E2">
          <title>Participants Same to arm1</title>
          <description>Diagnostic capabilities of AFI in the diagnosis of GERD</description>
        </group>
        <group group_id="E3">
          <title>Participants Same to Previous Arm</title>
          <description>Diagnostic capabilities of GerdQ in the diagnosis of GERD</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Weifeng Wang</name_or_title>
      <organization>ChinaPLAGH</organization>
      <phone>0086-13911952018</phone>
      <email>wangwf301@hotmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

